Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Daiichi Sankyo Company, Limited
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Dato-DXd === Trophoblast cell surface antigen 2 (TROP2) is highly expressed on a variety of epithelial tumours and correlates with a poor prognosis, Dato-DXd is being developed as a novel TROP2-directed ADC. Dato-DXd demonstrated potent antitumor activity against TROP2-expressing tumors via efficent payload delivery into tumors alongside acceptable safety profiles in preclinical models, suggesting Dato-DXd could be a valuable treatment as it demonstrated a statistically significant improvement in progression-free surivival. '''However,''' recent results suggest that early on in treatment, Dato-DXd is not '''significantly''' better than the current standard of care chemotherapy. Daiichi Sankyo has a variety of Dato-DXd products currently in different phases of clinical trials: ==== Phase 1: ==== * TROPION-PanTumor01 - solid tumours * TROPION-PanTumor02 - '''NSCLC (Non-small cell lung cancer)''', '''TNBC (Triple negative breast cancer)''' * TROPION-Lung02 - NSCLC * TROPION-Lung04 - NSCLC * PETRA (AZD5305 combo) - solid tumors ==== Phase 2: ==== * TROPION-PanTumor03 - solid tumors * TROPION-Lung05 - NSCLC * BEGONIA - TNBC * ORCHARD - EGFR (Epidermal Growth Factor Receptor) mutated NSCLC * NeoCOAST-2 - <u>recectable</u>* early-stage NSCLC (durvamulab combo) <u>neoadjuvant</u>** <nowiki>*</nowiki>able to be removed via surgery <nowiki>**</nowiki>treatment given as first step to shrink tumour ==== Phase 3: ==== * TROPION-Lung01 - NSCLC * TROPION-Lung07 - <u>non-squamous</u>* NSCLC * TROPION-Lung08 - NSCLC * TROPION-Breast01 - BC (HR+, HER2 low or negative BC) * TROPION-Breast02 - '''TNBC (Triple negative breast cancer)''' * TROPION-Breast03 - TNBC (mono or durvalumab combo) <u>adjuvant</u>** <nowiki>*</nowiki>either Adenocarcinomas or large cell (undifferentiated) carcinomas <nowiki>**</nowiki> treatment given after main treatment to reduce chance of cancer returning by destroying any remaining cancer cells A list of Dato-DXd drugs currently in clinical trials can be found [https://www.daiichisankyo.com/files/rd/pipeline/index/pdf/pipeline2304_en.pdf here] in blue.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)